



Ranitidine 150 mg Tablets

The Issue: NH pharmacy has received notice from Pharmascience (PMS) that their brand of oral ranitidine 150 mg tablets have demonstrated compliance to Health Canada requirements for NDMA limits and are cleared for distribution and use.

Availability: Tablets are currently available at the hospital in Prince George, and will be available at other NH facilities within the following week. NH pharmacy has approximately 6 week supply of tablets based on historical use. Until other manufacturers return to market, there may be ongoing supply constraints on PMS product due to increased demand.

Practice Implications: Clinicians should be aware of the current availability of PMS brand ranitidine 150 mg tablets.

- Patients who were switched to a PPI due to the ranitidine recall can now be switched back to oral ranitidine; however, please continue to assess patient suitability for de-escalation of therapy (e.g. antacids) and consider non-medication interventions as appropriate (e.g. avoid dietary triggers, elevate head of bed).
- The therapeutic interchange for non-formulary H2-receptor antagonists to ranitidine has been reinstated.

Note:

- Ranitidine injectable: remains **restricted** to use in BC Cancer Agency protocols involving paclitaxel, angioedema treatment, and pre-op medication prior to C-sections/surgery in required patients

February 14, 2020 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage Update	✓	For further information contact: Jessica Brecknock or Ryan Doerksen Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		